Anticoagulation for CRRT in Patients with Thrombocytopenia

Assessment of Bleeding Risk in Thrombocytopenia

Thrombocytopenia represents an increased bleeding risk that should be considered when selecting an anticoagulation strategy for CRRT, according to the American Journal of Kidney Diseases 1, 2
The decision to use anticoagulation should be based on assessment of the patient's potential risks and benefits from anticoagulation, not solely on platelet count, as recommended by the American Journal of Kidney Diseases 3
Patients with thrombocytopenia have impaired coagulation, which affects the anticoagulation approach during CRRT, as noted by the American Journal of Kidney Diseases 4

Regional citrate anticoagulation is recommended for thrombocytopenic patients without contraindications to citrate, as suggested by Praxis Medical Insights 5, 6
Avoid citrate in patients with severe liver dysfunction due to impaired citrate metabolism, according to Praxis Medical Insights 5, 6
If citrate is contraindicated, consider running CRRT without anticoagulation rather than using heparin, as recommended by the American Journal of Kidney Diseases and Praxis Medical Insights 3, 6

For patients with heparin-induced thrombocytopenia (HIT), all heparin must be stopped, as recommended by the American Journal of Kidney Diseases 3, 4
In HIT patients, use direct thrombin inhibitors (such as argatroban) or Factor Xa inhibitors (danaparoid or fondaparinux), according to the American Journal of Kidney Diseases and Praxis Medical Insights 3, 6
For HIT patients without severe liver failure, argatroban is preferred over other thrombin or Factor Xa inhibitors, as suggested by the American Journal of Kidney Diseases and Praxis Medical Insights 3, 6

Monitor systemic acid-base balance regularly, particularly in patients at high risk for citrate accumulation, as recommended by Praxis Medical Insights 5
Track serum sodium levels to prevent hypernatremia, which can occur with citrate anticoagulation, according to Praxis Medical Insights 5
For patients with liver dysfunction receiving citrate, closely monitor for signs of citrate accumulation by following systemic ionized calcium levels, as suggested by Praxis Medical Insights 5

Implement a strict protocol for citrate anticoagulation with adequate staff education to avoid prescription errors, as recommended by Praxis Medical Insights 5
Use dialysate and replacement fluids with appropriate electrolyte composition, particularly with increased magnesium concentration when using regional citrate anticoagulation, according to Praxis Medical Insights 5
Monitor for common electrolyte abnormalities associated with CRRT including hypophosphatemia, hypokalemia, and hypomagnesemia, as suggested by Praxis Medical Insights 5
Pay particular attention to magnesium levels, as magnesium can be lost in the effluent as magnesium-citrate complexes during regional citrate anticoagulation, according to Praxis Medical Insights 5

Regional citrate anticoagulation is the preferred strategy over heparin or no anticoagulation for patients in whom citrate is not contraindicated, with a Grade 2C recommendation. 7
Continuous renal replacement therapy (CRRT) can be performed without heparin in patients with high bleeding risk or coagulopathy by using regional citrate anticoagulation as first‑line, or by omitting anticoagulation entirely when citrate is contraindicated. 7

Severe liver dysfunction that impairs citrate metabolism constitutes a contraindication to the use of citrate anticoagulation. 7

In patients with confirmed or suspected HIT, all heparin products should be stopped immediately and anticoagulation should be provided with a direct thrombin inhibitor (e.g., argatroban) or a Factor Xa inhibitor (e.g., danaparoid, fondaparinux), supported by a Grade 1A recommendation. 7
For HIT patients without severe liver failure, argatroban is the preferred anticoagulant over other alternatives, with a Grade 2C recommendation. 7

The KDIGO clinical practice guidelines assign a Grade 1B recommendation for anticoagulation in standard‑risk CRRT patients and a Grade 2C recommendation for citrate anticoagulation in high‑bleeding‑risk patients. 7
Regional heparinization should be avoided in patients with increased bleeding risk because its systemic effects are unpredictable in critical illness; this is a Grade 2C recommendation. 7